Dressler F, Grävinghoff L, Grütte E, Jüngst B K, Liersch R, Nomayo H, Puls I, Rautenburg H W, Schmaltz A, Schumacher G
Monatsschr Kinderheilkd. 1985 Mar;133(3):154-7.
Antiarrhythmic treatment was required in 35 patients aged one day to 11 8/12 years (average 5 7/12 years) for one or several of the following arrhythmias: paroxysmal supraventricular tachycardia (17), ventricular extrasystole (16), ventricular tachycardia (17), ventricular extrasystole (16), ventricular tachycardia (4), junctional tachycardia (4), and atrial flutter (3). 300 mg/m2/day oral propafenone was administered in 3 to 4 divided doses. The arrhythmia in 21 of the 35 patients had been unsuccessfully treated by digoxin (6), verapamil (5), ajmalin (4), propranolol (3), spartein (1), phenytoin (1), and lidocain (1) prior to the propafenone therapy. However, the arrhythmias could be abolished or reduced in 30 patients (85.7%) by Propafenone. In 5 patients with supraventricular tachycardia (2), junctional tachycardia (2), or ventricular extrasystole (1), propafenone therapy had no effect. In two other patients propafenone led to atrioventricular conduction disturbances and had to be discontinued. Propafenone is an effective well tolerated antiarrhythmic drug without major side effects in pediatric patients.
35名年龄在1天至11又8/12岁（平均5又7/12岁）的患者因以下一种或几种心律失常需要进行抗心律失常治疗：阵发性室上性心动过速（17例）、室性早搏（16例）、室性心动过速（4例）、交界性心动过速（4例）和心房扑动（3例）。口服普罗帕酮，剂量为300mg/m²/天，分3至4次服用。在35例患者中，有21例在接受普罗帕酮治疗前，曾使用地高辛（6例）、维拉帕米（5例）、阿马林（4例）、普萘洛尔（3例）、司巴丁（1例）、苯妥英（1例）和利多卡因（1例）治疗心律失常，但均未成功。然而，普罗帕酮可使30例患者（85.7%）的心律失常得到消除或减轻。在5例室上性心动过速（2例）、交界性心动过速（2例）或室性早搏（1例）患者中，普罗帕酮治疗无效。在另外2例患者中，普罗帕酮导致房室传导障碍，不得不停药。普罗帕酮是一种有效的抗心律失常药物，在儿科患者中耐受性良好，无严重副作用。
